Emile E. Voest

38.0k total citations · 8 hit papers
370 papers, 18.8k citations indexed

About

Emile E. Voest is a scholar working on Oncology, Cancer Research and Molecular Biology. According to data from OpenAlex, Emile E. Voest has authored 370 papers receiving a total of 18.8k indexed citations (citations by other indexed papers that have themselves been cited), including 196 papers in Oncology, 149 papers in Cancer Research and 138 papers in Molecular Biology. Recurrent topics in Emile E. Voest's work include Cancer Genomics and Diagnostics (74 papers), Angiogenesis and VEGF in Cancer (55 papers) and Cancer, Hypoxia, and Metabolism (51 papers). Emile E. Voest is often cited by papers focused on Cancer Genomics and Diagnostics (74 papers), Angiogenesis and VEGF in Cancer (55 papers) and Cancer, Hypoxia, and Metabolism (51 papers). Emile E. Voest collaborates with scholars based in Netherlands, United States and Germany. Emile E. Voest's co-authors include Jeanine M.L. Roodhart, Martijn F.B.G. Gebbink, Alexander de Graeff, Saskia Teunissen, Krijn K. Dijkstra, René H. Medema, Rachel H. Giles, Judah Folkman, Martijn P. Lolkema and Robert J. D’Amato and has published in prestigious journals such as Nature, New England Journal of Medicine and Cell.

In The Last Decade

Emile E. Voest

364 papers receiving 18.4k citations

Hit Papers

Chemotherapy, Bevacizumab, and Cetuximab in Met... 1995 2026 2005 2015 2009 2007 1995 2017 2018 250 500 750 1000
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Chemotherapy, Bevacizumab, and Cetuximab in Metastatic Colorectal Cancer
    2009 1.0k citations Emile E. Voest et al. profile →
  2. Symptom Prevalence in Patients with Incurable Cancer: A Systematic Review
    2007 729 citations Emile E. Voest et al. profile →
  3. Inhibition of Angiogenesis In Vivo by Interleukin 12
    1995 614 citations Emile E. Voest et al. profile →
  4. Tumor Organoids as a Pre-clinical Cancer Model for Drug Discovery
    2017 381 citations Fleur Weeber, Salo Ooft et al. profile →
  5. Low and variable tumor reactivity of the intratumoral TCR repertoire in human cancers
    2018 373 citations Wouter Scheper, Pétur Snæbjörnsson et al. profile →
  6. Tumor organoids: Opportunities and challenges to guide precision medicine
    2021 209 citations Emile E. Voest et al. profile →
  7. Delivering precision oncology to patients with cancer
    2022 197 citations Emile E. Voest et al. profile →
  8. A pan-cancer analysis of the microbiome in metastatic cancer
    2024 94 citations Thomas Battaglia, Laurien J. Zeverijn et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Emile E. Voest Netherlands 70 8.5k 7.3k 4.9k 3.1k 1.9k 370 18.8k
Michael J. Duffy Ireland 77 8.0k 0.9× 9.0k 1.2× 7.0k 1.4× 2.8k 0.9× 1.5k 0.8× 264 19.1k
William D. Figg United States 86 10.0k 1.2× 11.5k 1.6× 3.4k 0.7× 4.4k 1.4× 2.5k 1.3× 604 25.3k
Patrice Viens France 61 10.5k 1.2× 6.0k 0.8× 5.6k 1.1× 2.8k 0.9× 2.2k 1.2× 353 17.5k
Naoto T. Ueno United States 72 11.0k 1.3× 5.6k 0.8× 6.5k 1.3× 3.7k 1.2× 2.6k 1.4× 547 20.4k
David W. Hedley Canada 66 6.6k 0.8× 6.9k 0.9× 5.1k 1.0× 2.9k 0.9× 1.2k 0.6× 322 17.2k
Masakazu Toi Japan 68 10.8k 1.3× 8.0k 1.1× 6.9k 1.4× 6.1k 2.0× 2.1k 1.1× 666 21.5k
Andrew K. Godwin United States 79 6.0k 0.7× 13.4k 1.8× 5.2k 1.1× 2.5k 0.8× 1.7k 0.9× 386 22.4k
Patricia LoRusso United States 69 11.2k 1.3× 10.9k 1.5× 2.8k 0.6× 4.4k 1.4× 2.0k 1.0× 569 21.9k
Hong Wang United States 80 6.9k 0.8× 9.9k 1.4× 3.1k 0.6× 3.4k 1.1× 4.1k 2.2× 749 25.2k
C. Patrick Reynolds United States 74 5.0k 0.6× 12.7k 1.7× 4.8k 1.0× 2.2k 0.7× 2.6k 1.4× 338 21.8k

Countries citing papers authored by Emile E. Voest

Since Specialization
Citations

This map shows the geographic impact of Emile E. Voest's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Emile E. Voest with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Emile E. Voest more than expected).

Fields of papers citing papers by Emile E. Voest

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Emile E. Voest. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Emile E. Voest. The network helps show where Emile E. Voest may publish in the future.

Co-authorship network of co-authors of Emile E. Voest

This figure shows the co-authorship network connecting the top 25 collaborators of Emile E. Voest. A scholar is included among the top collaborators of Emile E. Voest based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Emile E. Voest. Emile E. Voest is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Geurts, Birgit S., Laurien J. Zeverijn, Jade M. van Berge Henegouwen, et al.. (2024). Characterization of discordance between mismatch repair deficiency and microsatellite instability testing may prevent inappropriate treatment with immunotherapy. The Journal of Pathology. 263(3). 288–299. 4 indexed citations
2.
Doorn-Khosrovani, Sahar Barjesteh van Waalwijk van, Hans Timmer, Karin Verkerk, et al.. (2024). 1550P Addressing uncertainties of clinical value and improving access for newly authorised indications through DRUG-Access Protocol (DAP)-like platforms: Joint collection and evaluation of real-world evidence. Annals of Oncology. 35. S943–S944. 1 indexed citations
3.
Henegouwen, Jade M. van Berge, Laurien J. Zeverijn, Birgit S. Geurts, et al.. (2024). Maximizing Treatment Opportunities: Assessing Protocol Waivers’ Impact on Safety and Outcome in the Drug Rediscovery Protocol. Clinical Cancer Research. 30(17). 3937–3943. 1 indexed citations
4.
Edsjö, Anders, Birgit Geoerger, Frédérique Nowak, et al.. (2023). Precision cancer medicine: Concepts, current practice, and future developments. Journal of Internal Medicine. 294(4). 455–481. 31 indexed citations
5.
Geurts, Birgit S., Laurien J. Zeverijn, Gijs F. de Wit, et al.. (2023). Efficacy and Safety of Panitumumab in Patients With RAF/RAS-Wild-Type Glioblastoma: Results From the Drug Rediscovery Protocol. The Oncologist. 29(5). 431–440. 3 indexed citations
6.
Cattaneo, Chiara M., Thomas Battaglia, Jos Urbanus, et al.. (2023). Identification of patient-specific CD4+ and CD8+ T cell neoantigens through HLA-unbiased genetic screens. Nature Biotechnology. 41(6). 783–787. 27 indexed citations
7.
Zhang, Zhengkui, Xiangjun Kong, Maarten A. Ligtenberg, et al.. (2022). RNF31 inhibition sensitizes tumors to bystander killing by innate and adaptive immune cells. Cell Reports Medicine. 3(6). 100655–100655. 30 indexed citations
8.
Samsom, Kris G., Linda J.W. Bosch, Luuk J. Schipper, et al.. (2020). Study protocol: Whole genome sequencing Implementation in standard Diagnostics for Every cancer patient (WIDE). BMC Medical Genomics. 13(1). 169–169. 24 indexed citations
9.
Roosmalen, Markus J. van, Nizar Hami, Ingrid Verlaan-Klink, et al.. (2020). Diverse BRAF Gene Fusions Confer Resistance to EGFR-Targeted Therapy via Differential Modulation of BRAF Activity. Molecular Cancer Research. 18(4). 537–548. 11 indexed citations
10.
Kloosterman, Wigard P., Robert R.J. Coebergh van den Braak, Mark Pieterse, et al.. (2017). A Systematic Analysis of Oncogenic Gene Fusions in Primary Colon Cancer. Cancer Research. 77(14). 3814–3822. 67 indexed citations
11.
Tabernero, Josep, Malvika Vyas, Rosa Giuliani, et al.. (2016). Biosimilars: a position paper of the European Society for Medical Oncology, with particular reference to oncology prescribers. ESMO Open. 1(6). e000142–e000142. 88 indexed citations
12.
Kemper, Kristel, Oscar Krijgsman, Paulien Cornelissen‐Steijger, et al.. (2015). Intra‐ and inter‐tumor heterogeneity in a vemurafenib‐resistant melanoma patient and derived xenografts. EMBO Molecular Medicine. 7(9). 1104–1118. 103 indexed citations
13.
Moreno, Víctor, David Olmos, Carlos Gomez‐Roca, et al.. (2014). Dose–Response Relationship in Phase I Clinical Trials: A European Drug Development Network (EDDN) Collaboration Study. Clinical Cancer Research. 20(22). 5663–5671. 14 indexed citations
14.
Daenen, Laura G.M., Julia M. Houthuijzen, Geert A. Cirkel, et al.. (2013). Treatment-induced host-mediated mechanisms reducing the efficacy of antitumor therapies. Oncogene. 33(11). 1341–1347. 30 indexed citations
15.
Daenen, Laura G.M., Jeanine M.L. Roodhart, Miranda van Amersfoort, et al.. (2011). Chemotherapy Enhances Metastasis Formation via VEGFR-1–Expressing Endothelial Cells. Cancer Research. 71(22). 6976–6985. 142 indexed citations
16.
Vermaat, Joost S.P., Isaäc J. Nijman, Marco J. Koudijs, et al.. (2011). Primary Colorectal Cancers and Their Subsequent Hepatic Metastases Are Genetically Different: Implications for Selection of Patients for Targeted Treatment. Clinical Cancer Research. 18(3). 688–699. 119 indexed citations
17.
Rooijen, Ellen van, Emile E. Voest, Ive Logister, et al.. (2009). Zebrafish mutants in the von Hippel-Lindau tumor suppressor display a hypoxic response and recapitulate key aspects of Chuvash polycythemia. Blood. 113(25). 6449–6460. 112 indexed citations
18.
Shaked, Yuval, Terence Tang, Jill Woloszynek, et al.. (2009). Contribution of Granulocyte Colony-Stimulating Factor to the Acute Mobilization of Endothelial Precursor Cells by Vascular Disrupting Agents. Cancer Research. 69(19). 7524–7528. 64 indexed citations
19.
Beerepoot, Laurens V., Sandra A. Radema, Els O. Witteveen, et al.. (2006). Phase I Clinical Evaluation of Weekly Administration of the Novel Vascular-Targeting Agent, ZD6126, in Patients With Solid Tumors. Journal of Clinical Oncology. 24(10). 1491–1498. 89 indexed citations
20.
Łoś, Marek, Thera P. Links, Jacques W.M. Lenders, & Emile E. Voest. (2000). De ziekte van Von Hippel-Lindau. Nederlandsch tijdschrift voor geneeskunde/Nederlands tijdschrift voor geneeskunde/NTvG-databank. 144(11). 497–501. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Michael J. Duffy Breakdown of academic impact, for papers by William D. Figg Breakdown of academic impact, for papers by Patrice Viens Breakdown of academic impact, for papers by Naoto T. Ueno Breakdown of academic impact, for papers by David W. Hedley Breakdown of academic impact, for papers by Masakazu Toi Breakdown of academic impact, for papers by Andrew K. Godwin Breakdown of academic impact, for papers by Patricia LoRusso Breakdown of academic impact, for papers by Hong Wang Breakdown of academic impact, for papers by C. Patrick Reynolds
Rankless by CCL
2026